T. Rowe Price Associates
PRTK

T. Rowe Price Associates’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

T. Rowe Price Associates’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,450
Closed -$101K – 2604
2018
Q3 		$101K Buy
10,450
+185
+2% +$1.87K ﹤0.01% 2533
2018
Q2 		$105K Buy
10,265
+53
+0.5% +$600 ﹤0.01% 2521
2018
Q1 		$133K Buy
+10,212
New +$152K ﹤0.01% 2470

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates's PRTK Position: Q4 2018 in Review

T. Rowe Price Associates sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 10,450 shares — an estimated $101K sold.

T. Rowe Price Associates first reported a position in PRTK in Q1 2018 and held it in 3 quarters. The position peaked at $133K in Q1 2018. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • T. Rowe Price Associates reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 10,450 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $101K.
  • T. Rowe Price Associates first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • T. Rowe Price Associates's Paratek Pharmaceuticals, Inc. position peaked at $133K in Q1 2018.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.